Long-Term Safety Extension Study of ACTIMMUNE (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia

Trial Profile

Long-Term Safety Extension Study of ACTIMMUNE (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia

Discontinued
Phase of Trial: Phase III

Latest Information Update: 26 Apr 2017

At a glance

  • Drugs Interferon gamma-1b (Primary)
  • Indications Friedreich's ataxia
  • Focus Adverse reactions
  • Acronyms STEADFAST Long-Term Safety Extension
  • Sponsors Horizon Pharma
  • Most Recent Events

    • 24 Feb 2017 Planned End Date changed from 1 Jun 2018 to 1 Jun 2017.
    • 24 Feb 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2017.
    • 08 Dec 2016 Status changed from recruiting to discontinued. According to a Horizon Pharma media release, the company in conjunction with the independent Data Safety Monitoring Board, the principal investigator and the Friedreich's Ataxia Research Alliance (FARA) Collaborative Clinical Research Network (CCRN) in FA, has determined that, based on the results from a parent phase III study (profile 700251922), the FA (Friedreich's ataxia) development program will be discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top